Psyence Biomedical Ltd. Common Shares (PBM) is a publicly traded Healthcare sector company. As of October 5, 2026, PBM trades at $5.50 with a market cap of $19.68M and a P/E ratio of 0.00. PBM moved +6.51% today. Year to date, PBM is +3.71%; over the trailing twelve months it is -73.28%. Its 52-week range spans $1.92 to $74.94. Rallies surfaces PBM's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Psyence BioMed partners with Benuvia to make pharmaceutical-grade ibogaine in Texas: Psyence Biomedical’s Texas unit signed an agreement with Benuvia to manufacture pharmaceutical-grade ibogaine in the United States. Benuvia estimates it holds about half of the U.S. aggregate production quota for ibogaine, while production timing depends on DEA quotas and other regulatory authorizations.
| Metric | Value |
|---|---|
| Price | $5.50 |
| Market Cap | $19.68M |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $74.94 |
| 52-Week Low | $1.92 |
| Volume | 24.20K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
PBM analyst coverage data. Average price target: $0.00.